Fausto Andres Bustos Carrillo

Fausto Andres Bustos Carrillo

Auto-generated profile, based on publicly available information

Fausto Andres Bustos Carrillo

Division of Infectious Diseases and Vaccinology, School of Public Health, University of California

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2020 in Science
Verified
Journal Article
Closed access
LKLeah C. Katzelnick
Leah C. Katzelnick
CNCésar Narvaez
César Narvaez
SASonia Arguello
Sonia Arguello
BMBrenda Lopez Mercado
Brenda Lopez Mercado
DCDamaris Collado
Damaris Collado
EHEva Harris
Eva Harris
Double whammy: Dengue and Zika virus epidemics have been lapping each other around the globe. These are closely related mosquito-borne viruses with about 40% homology within the envelope protein. We know that subsequent dengue infections bring a risk of antibody-dependent disease enhancement. Whereas emphasis has been placed on how prior dengue immunity affects Zika infection, little is known about how prior Zika immunity may affect dengue disease. Katzelnick et al. have been following a well-characterized and established pediatric cohort in Nicaragua who were serially exposed to both flaviviruses in recent years (see the Perspective by Clapham). This study shows not only that a previous history of just one round of dengue is a problem but also that prior Zika immunity creates an increased risk for severe dengue virus sereotype 2 infection. By contrast, multiple infections raise antibodies to protective levels. Science , this issue p. 1123 ; see also p. 1055

6 May 2018 in Biological Reviews
Verified
Journal Article
Closed access
PDF file
CCColin Carlson
Colin Carlson
WGWayne Getz
Wayne Getz
KKKyrre L. Kausrud
Kyrre L. Kausrud
CCCarrie A. Cizauskas
Carrie A. Cizauskas
JBJason K. Blackburn
Jason K. Blackburn
NSNils Chr. Stenseth
Nils Chr. Stenseth

27 August 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JZJose Victor Zambrana
Jose Victor Zambrana
FCFausto Bustos Carrillo
Fausto Bustos Carrillo
RBRaquel Burger-Calderon
Raquel Burger-Calderon
DCDamaris Collado
Damaris Collado
NSNery Sanchez
Nery Sanchez
EHEva Harris
Eva Harris
In 2015, a Zika epidemic in Brazil began spreading throughout the Americas. Zika virus (ZIKV) entered Managua, Nicaragua, in January 2016 and caused an epidemic that peaked in July–September 2016. ZIKV seropositivity was estimated among participants of pediatric (n = 3,740) and household (n = 2,147) cohort studies, including an adult-only subset from the household cohort (n = 1,074), in Managua. Seropositivity was based on a highly sensitive and specific assay, the Zika NS1 blockade-of-binding ELISA, which can be used in dengue-endemic populations. Overall seropositivity for the pediatric (ages 2–14), household (ages 2–80), and adult (ages 15–80) cohorts was 36, 46, and 56%, respectively. Trend, risk factor, and contour mapping analyses demonstrated that ZIKV seroprevalence increased nonlinearly with age and that body surface area was statistically associated with increasing seroprevalence in children. ZIKV seropositivity was higher in females than in males across almost all ages, with adjusted prevalence ratios in children and adults of 1.11 (95% CI: 1.02–1.21) and 1.14 (95% CI: 1.01–1.28), respectively. No household-level risk factors were statistically significant in multivariate analyses. A spatial analysis revealed a 10–15% difference in the risk of ZIKV infections across our 3-km-wide study site, suggesting that ZIKV infection risk varies at small spatial scales. To our knowledge, this is the largest ZIKV seroprevalence study reported in the Americas, and the only one in Central America and in children to date. It reveals a high level of immunity against ZIKV in Managua as a result of the 2016 epidemic, making a second large Zika epidemic unlikely in the near future. Significance Seroprevalence studies are important for determining risk factors for infection and for assessing the susceptible fraction of a population after an epidemic has swept through a population. Here, Zika virus (ZIKV) seroprevalence was estimated among participants of a pediatric cohort, a separate household cohort, and an adult-only subset from the household cohort, in Managua, Nicaragua, after the 2016 Zika epidemic, yielding 36, 46, and 56% seropositivity, respectively. To our knowledge, this is the only ZIKV seroprevalence study reported in Central America and the largest in the Americas and in a pediatric population to date. The explosive 2016 Zika epidemic resulted in a high level of seropositivity to ZIKV, making a second large Zika epidemic in Managua in the near future unlikely.

20 July 2017 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
AGAimee L Geissler
Aimee L Geissler
FCFausto Bustos Carrillo
Fausto Bustos Carrillo
KSKrista Swanson
Krista Swanson
MPMary E Patrick
Mary E Patrick
KFKathleen E Fullerton
Kathleen E Fullerton
BMBarbara E Mahon
Barbara E Mahon
Campylobacteriosis, a leading cause of foodborne illness in the United States, was not nationally notifiable until 2015. Data describing national patterns and trends are limited. We describe the epidemiology of Campylobacter infections in the United States during 2004–2012. We summarized laboratory-confirmed campylobacteriosis data from the Nationally Notifiable Disease Surveillance System, National Outbreak Reporting System, National Antimicrobial Resistance Monitoring System, and Foodborne Diseases Active Surveillance Network. During 2004–2012, 303520 culture-confirmed campylobacteriosis cases were reported. Average annual incidence rate (IR) was 11.4 cases/100000 persons, with substantial variation by state (range, 3.1–47.6 cases/100000 persons). IRs among patients aged 0–4 years were more than double overall IRs. IRs were highest among males in all age groups. IRs in western states and rural counties were higher (16.2/100000 and 14.2/100000, respectively) than southern states and metropolitan counties (6.8/100000 and 11.0/100000, respectively). Annual IRs increased 21% from 10.5/100000 during 2004–2006 to 12.7/100000 during 2010–2012, with the greatest increases among persons aged >60 years (40%) and in southern states (32%). The annual median number of Campylobacter outbreaks increased from 28 in 2004–2006 to 56 in 2010–2012; in total, 347 were reported. Antimicrobial susceptibility testing of isolates from 4793 domestic and 1070 travel-associated infections revealed that, comparing 2004–2009 to 2010–2012, ciprofloxacin resistance increased among domestic infections (12.8% vs 16.1%). During 2004–2012, incidence of campylobacteriosis, outbreaks, and clinically significant antimicrobial resistance increased. Marked demographic and geographic differences exist. Our findings underscore the importance of national surveillance and understanding of risk factors to guide and target control measures.

6 October 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
LKLeah C. Katzelnick
Leah C. Katzelnick
JZJose Victor Zambrana
Jose Victor Zambrana
DEDouglas Elizondo
Douglas Elizondo
DCDamaris Collado
Damaris Collado
NGNadezna Garcia
Nadezna Garcia
EHEva Harris
Eva Harris
Unexpectedly, cross-reactive antibodies are stable or rise after primary dengue and Zika virus infection and wane slowly after secondary infection.

15 February 2019 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
FCFausto Bustos Carrillo
Fausto Bustos Carrillo
DCDamaris Collado
Damaris Collado
NSNery Sanchez
Nery Sanchez
SOSergio Ojeda
Sergio Ojeda
BMBrenda Lopez Mercado
Brenda Lopez Mercado
EHEva Harris
Eva Harris
Chikungunya virus (CHIKV) is an understudied threat to human health. During the 2015 chikungunya epidemic in Managua, Nicaragua, we estimated the ratio of symptomatic to asymptomatic CHIKV infections, which is important for understanding transmission dynamics and the public health impact of CHIKV. This index cluster study identified and monitored persons at risk of infection, enabling capture of asymptomatic infections. We estimated that 31 (49%) of 63 at-risk participants had asymptomatic CHIKV infections, which is significantly outside the 3% to 28% range reported in literature reviews. However, recent seroprevalence studies, including two large pediatric cohort studies in the same setting, had also found percentages of inapparent infections outside the 3% to 28% range. Bayesian and simulation analyses, informed by a systematic literature search, revealed that the percentage of inapparent infections in epidemic settings varies by CHIKV phylogenetic lineage. Our study quantifies and provides the first epidemiological evidence that chikungunya epidemic characteristics are strongly influenced by CHIKV lineage.